Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sri Lanka’s Branded-Drug Ban Seen As Boon To India’s Generics (India)

This article was originally published in PharmAsia News

Executive Summary

Sri Lanka's decision to ban prescriptions for branded drugs is viewed by India's generic-drugs industry as beneficial to its companies. A "trade source" said the move means India, as the leading country for generic drugs, will be the primary beneficiary. He noted that half of the drugs imported by Sri Lanka not only are made in India; nearly all Indian medicines are imported into the country. Sri Lanka's intention in ordering physicians to prescribe only generics was to force down the prices of drugs. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel